Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide vs Insulin Glargine for Liver Fat in T2DM with NAFLD
NCT02303730Phase 4Completed
- Sponsor
- Fudan University
- Start
- Mar 2015
- Primary completion
- Nov 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of exenatide in type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by Fudan University. Primary endpoint: Change in liver fat content at 24 weeks. Started Mar 2015; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02303730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02303730.